United Therapeutics Corporation (UTHR) : Amici Capital reduced its stake in United Therapeutics Corporation by 24.58% during the most recent quarter end. The investment management company now holds a total of 95,365 shares of United Therapeutics Corporation which is valued at $12,812,288 after selling 31,086 shares in United Therapeutics Corporation , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.United Therapeutics Corporation makes up approximately 4.87% of Amici Capital’s portfolio.
Other Hedge Funds, Including , Signaturefd boosted its stake in UTHR in the latest quarter, The investment management firm added 192 additional shares and now holds a total of 226 shares of United Therapeutics Corporation which is valued at $30,363.Schroder Investment Management Group reduced its stake in UTHR by selling 34,802 shares or 7.1% in the most recent quarter. The Hedge Fund company now holds 455,375 shares of UTHR which is valued at $59,189,643. United Therapeutics Corporation makes up approx 0.11% of Schroder Investment Management Group’s portfolio.Globeflex Capital L P reduced its stake in UTHR by selling 1,500 shares or 10.98% in the most recent quarter. The Hedge Fund company now holds 12,160 shares of UTHR which is valued at $1,580,557. United Therapeutics Corporation makes up approx 0.40% of Globeflex Capital L P’s portfolio. Stevens Capital Management Lp added UTHR to its portfolio by purchasing 10,411 company shares during the most recent quarter which is valued at $1,244,635. United Therapeutics Corporation makes up approx 0.05% of Stevens Capital Management Lp’s portfolio.New Amsterdam Partnersny boosted its stake in UTHR in the latest quarter, The investment management firm added 4,139 additional shares and now holds a total of 46,408 shares of United Therapeutics Corporation which is valued at $5,519,768. United Therapeutics Corporation makes up approx 1.34% of New Amsterdam Partnersny’s portfolio.
United Therapeutics Corporation closed down -2.57 points or -1.92% at $130.94 with 4,55,716 shares getting traded on Monday. Post opening the session at $133.5, the shares hit an intraday low of $130.49 and an intraday high of $133.5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, United Therapeutics Corporation reported $4.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.43 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $3.93. The company had revenue of $408.20 million for the quarter, compared to analysts expectations of $402.93 million. The company’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.55 EPS.
Many Wall Street Analysts have commented on United Therapeutics Corporation. United Therapeutics Corporation was Upgraded by Ladenburg Thalmann to ” Buy” on Oct 28, 2016.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.